Internal Medicine, Endocrinology, Diabetes, & Metabolism · Du Bois, PA
NPI
1912915554
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
145 Hospital Ave, Suite 300
Du Bois, PA, 15801
Phone (814) 375-4089
Groups this clinician bills Medicare through
Medicare paid, 2024
$29K
472 services
Medicare patients, 2024
307
Average age 73
Drug cost, 2024
$2.8M
7,183 prescriptions
Company payments, 2025
$1,102
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sarvesh Rajan was code 99214 (office e&m - established), 282 times for 183 patients. In total Sarvesh Rajan billed 472 services in 8 codes, and Medicare paid $29K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-06-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 282 | 183 | $64.51 | $18K |
| 99213 Office E&M - Established | Facility | 101 | 89 | $43.89 | $4,433 |
| 99204 Office E&M - New | Facility | 58 | 58 | $91.62 | $5,314 |
| 95251 Test - Miscellaneous | Office | 19 | 16 | $26.24 | $499 |
By year: 2022 $41K for 540 services; 2023 $32K for 499 services; 2024 $29K for 472 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sarvesh Rajan prescribed most often to Medicare patients was Levothyroxine Sodium, with 686 prescriptions and refills. In total Sarvesh Rajan wrote 7,183 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 686 | 1,467 | 162 | $9,174 |
| Ozempic Semaglutide | 383 | 442 | 75 | $400K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 363 | 638 | 113 | $74K |
| Rosuvastatin Calcium Generic | 291 | 666 | 85 | $5,335 |
| Metformin Hcl Er Metformin Hcl | 286 | 566 | 66 | $4,857 |
| Metformin Hcl Generic | 282 | 664 | 81 | $3,659 |
| Trulicity Dulaglutide | 270 | 390 | 66 | $362K |
| Atorvastatin Calcium Generic | 261 | 550 | 69 | $2,988 |
| Ezetimibe Generic | 238 | 458 | 59 | $5,086 |
| Jardiance Empagliflozin | 227 | 333 | 53 | $190K |
| Novolog Flexpen Insulin Aspart | 220 | 343 | 80 | $59K |
| Humalog Kwikpen U-100 Insulin Lispro | 217 | 385 | 82 | $61K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 207 | 437 | 60 | $24K |
| Synthroid Levothyroxine Sodium | 180 | 313 | 40 | $12K |
| Methimazole Generic | 176 | 276 | 41 | $1,806 |
Brand drugs: 3,627 claims; generic drugs: 2,876 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sarvesh Rajan $1,102 ($1,102 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbott Laboratories with $199.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 5 | $199 |
| Lilly USA, LLC LLY | 5 | $91.75 |
| Novo Nordisk Inc NVO | 5 | $85.94 |
| Amgen Inc. AMGN | 4 | $74.57 |
| Abbvie Inc. ABBV | 3 | $61.26 |
| Madrigal Pharmaceuticals MDGL | 2 | $55.97 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $46.64 |
| Neurocrine BioSciences, Inc. NBIX | 2 | $44.83 |
| Antares Pharma, Inc. | 2 | $44.43 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $41.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.